Cardiovascular disease in human immunodeficiency virus.

摘要: With widespread access to high-quality medical care as in Australia, human immunodeficiency virus (HIV) is now considered a chronic, treatable condition, with good life expectancy. The use of combined highly active antiretroviral therapy has enabled effective suppression the virus, but also been associated increased cardiac morbidity and mortality. Over representation traditional risk factors, such hyperlipidaemia diabetes, well an incidence ischaemic non-ischaemic heart disease major concern treatment therapy. Therefore, contemporary management strategy for patients HIV must include prevention cardiovascular risk. This review will outline complex interplay between infection, drug regimens accelerated disease, particular focus on screening, options Australian population.